Pharmaceutical manufacturers, hospitals, pharmacies, medical practices, veterinary clinics, and any other business authorised to keep medicines and materials falling under Schedule 8/9 must meet strict legal requirements for storage.

When not in immediate use, S8/9 materials must be contained in a compliant drug safe or vault.

This also extends to the storage and handling of S8/9 medical product manufacturing waste awaiting the strictly regulated destruction process.  The regulatory (EPA/TGA) compliant destruction lead time can take as long as 6 – 8 months creating overflow storage and handling challenges for many pharmaceutical manufacturers requiring ongoing waste destruction.

BS3’s state-of-the-art temperature-controlled storage facility located in Melbourne, offers turn key storage and logistics solutions for scheduled medicines and medicinal products, Clinical Trial reverse logistics and now also caters to the growing demand for storage and handling of highly regulated S8/9 material waste.

With the appropriate licenses and extensive regulatory expertise, BS3 is equipped to meet the requirements of medicines scheduled 2, 3, 4, 8 & 9 across all areas from safe and vaulted storage, temperature control storage, security, handling, and distribution, right through to waste product storage and handling in key areas.

At BS3, we provide our clients across the pharmaceutical industry, the essential regulatory know how, combined with full-service capabilities, said BS3’s General Manager, Steve Limn.

This includes robust storage solutions that adhere to the strict legal requirements of safe or vaulted storage with the security required for products and waste that fall under S8/9.

For further information, media enquiries or interview requests contact:

T: 03 7036 0065 M: +61 499 319 847 

E: Steve.Limn@bs3.com.au | W:bs3.com.au